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Available online 11 January 2019Background: Bariatric surgery leads to early and long-lasting remission of type 2 diabetes (T2D). However, the
mechanisms behind this phenomenon remain unclear. Among several factors, gut hormones are thought to be
crucial mediators of this effect. Unlike GLP-1, the role of the hormone peptide tyrosine tyrosine (PYY) in bariatric
surgery in humans has been limited to appetite regulation and its impact on pancreatic islet secretory function
and glucose metabolism remains under-studied.
Methods: Changes in PYY concentrations were examined in obese patients after bariatric surgery and compared
to healthy controls. Human pancreatic islet function was tested upon treatment with sera from patients before
and after the surgery, in presence or absence of PYY. Alterations in intra-islet PYY release and insulin secretion
were analysed after stimulation with short chain fatty acids (SCFAs), bile acids and the cytokine IL-22.
Findings:We demonstrate that PYY is a key effector of the early recovery of impaired glucose-mediated insulin
and glucagon secretion in bariatric surgery. We establish that the short chain fatty acid propionate and bile
acids, which are elevated after surgery, can trigger PYY release not only from enteroendocrine cells but also
from human pancreatic islets. In addition, we identify IL-22 as a new factor which is modulated by bariatric sur-
gery in humans and which directly regulates PYY expression and release.
Interpretation: This study shows that somemajormetabolic benefits of bariatric surgery can be emulated ex vivo.
Our findings are expected to have a direct impact on the development of new non-surgical therapy for T2D
correction.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Bariatric surgery results in rapid and durable reversal of type 2
diabetes (T2D) and associated metabolic benefits in man [1].
Changes in gut hormones play a critical role in surgery-induced
metabolic improvements, which are independent of weight loss
[2]. In particular, post-operative elevation in the incretin hormone
GLP-1, has been reported to contribute to appetite suppression
and improved glycaemic control [2]. However, recent studies done
in rodents and humans have revealed the existence of GLP-1-
independent mechanisms, indicating that multiple cofactors mediate
the metabolic effects of surgery [3–7]. Moreover, increased levels ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Bariatric surgery areweight loss interventionswhich result in rapid
and durable reversal of type 2 diabetes (T2D) in man. Changes in
gut hormones play a critical role in surgery-induced metabolic
improvements.
The gut hormone, GLP-1 has been so far considered as the ‘holy
grail’ of this phenomenon although a number of studies have re-
ported that the beneficial effect of the surgery on glucose homeo-
stasis may not depend on GLP-1, thus challenging its unique role.
Like GLP-1, the release of the gut hormone PYY increases after
bariatric surgery. A common consensus posits that the main ef-
fect of this elevation in humans is on appetite regulation and
weight loss post operatively. However, latest evidence from stud-
ies done in rodents has shown that, PYY plays a major role in glu-
cose homeostasis and restoration of impaired islet function in
severely diabetic rats following Roux-En-Y gastric bypass
(RYGB). To date, the relationship between elevated circulating
PYY and the metabolic benefits of bariatric surgery on islet secre-
tory function has not been established in humans. Moreover, the
impact of factors altered by the surgery on PYY elevation is not
been fully characterized in man.
Added value of this study
Here we have examined the changes in PYY concentrations six
months after bariatric surgery in obese patients compared with
healthy control subjects, and their effects on human islet func-
tions. Using a translational approach that combines blood samples
from patients with T2D before and after surgery and isolated
donor human pancreatic islets, we demonstrate a significant ef-
fect of PYY on the improvement of islet secretory function post-
surgery. We establish that the short chain fatty acid propionate
and bile acids, which are elevated after surgery, can trigger PYY
release not only from enteroendocrine cells but also from human
pancreatic islets. In addition, we identify IL-22 as a new factor
which is modulated by bariatric surgery and which may directly
regulate PYY expression and release, elucidating some of the
mechanisms behind increased PYY concentrations after bariatric
surgery in humans.
Implications of all the available evidence
This study demonstrates that the metabolic benefits of bariatric
surgery on islet secretory functions can be emulated ex vivo, giv-
ing rise to the possibility of identifying the critical mediators of
these effects. Our findings that the gut hormone PYY mediates
some key anti-diabetic effects of bariatric surgery imply that a
pharmacological agent enhancing PYY release or its action could
provide an effective and non-surgical therapy for T2D. Moreover,
the identification of factors specifically triggering PYY induction
both systemically and within the islets, may pave the way for an
alternative cure to peptide therapeutics, thus overcoming their in-
herent weaknesses, like poor pharmacokinetic properties and sta-
bilities, and yet achieving the same benefits for the treatment of
diabetes.
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have been reported following bariatric surgery. This peptide hor-
mone was found to be central in the reversal of hyperglycaemiaand restoration of impaired insulin release following Roux-en-Y gas-
tric bypass (RYGB) in a rat model of T2D [8].
Both fasting and postprandial PYY levels increase significantly
within just one-week of RYGB or sleeve gastrectomy (SG) in obese pa-
tients, and remain elevated after 1 year [9–11]. These changes are asso-
ciated with normalization of fasting glucose levels, and improved blood
pressure, hypercholesterolemia and hypertriglyceridemia [12]. Chronic
treatment of human isolated islets from diabetic and non-diabetic
donors with exogenous PYY enhances glucose-mediated insulin secre-
tion and improves suppression of glucagon, suggesting a direct effect
of PYY on the correction of human diabetes [8,13]. However, the rela-
tionship between elevated circulating PYY and the metabolic benefits
of bariatric surgery on islet secretory function and diabetes reversal
has not been explored in humans.
PYY is mainly secreted from the L-cells of the ileum and colon in re-
sponse to food intake and, to a lesser extent, it is also expressed in the
delta-, PP- and alpha-cells of the pancreatic islets [13]. In clear contrast
to healthy islets, PYY content has recently been shown to be reduced by
50% in islets from theGoto-Kakizaki (GK) ratmodel of T2D, suggesting a
role of islet-derived PYY in health and diabetes [13]. Moreover, consis-
tentwith the changes in circulating levels, PYY content in islets ismark-
edly increased following RYGB in diabetic rats [13], potentially
contributing ing to RYGB-induced restoration of impaired islet
morphology and function. Several factors including accelerated nutrient
delivery to the intestine are likely to stimulate PYY secretion following
weight-loss surgery. Emerging evidence also suggests that alteration
in bile acids, and the intestinal microbiota and their metabolic products
can induce PYY release from enteroendocrine cells [14–17]. However,
whether they can also modulate secretion of PYY from pancreatic islets,
especially in humans is not known. One of the well-described effects of
bariatric surgery is a reduction in the chronic systemic inflammation as-
sociated with obesity. Indeed, levels of inflammatory cytokines, such as
IL-6 and TNFα decrease after bariatric surgery [18–20]. Unlike other cy-
tokines, interleukin-22 (IL-22), a small cytokine mainly produced by
Th1, Th17, Th22 and ILC3 cells, has been shown to alleviate metabolic
disorders in mice and protect pancreatic islet properties beyond its im-
munological functions [21,22]. Importantly, infusion of IL-22 in diet-
induced obese mice has been shown to result in elevated circulating
PYY levels, which in turn reduces food consumption. To date, the role
of IL-22 in weight-loss surgery and diabetes remission in man has not
been explored, and its potential impact on islet-derived PYY has not
been determined.
Here we have examined the changes in PYY concentrations six
months after bariatric surgery in obese patients compared with healthy
control subjects, and whether they can influence human islet secretory
functions. In addition, we have assessed the impact of short chain fatty
acids and bile acids on PYY release and glucose-mediated insulin secre-
tion from isolated pancreatic human islets. Finally, we have explored al-
terations in plasma IL-22 concentrations following bariatric surgery in
humans and modulation of PYY release from pancreatic islets by IL-22.
2. Materials and methods
2.1. Patients
All patients undergoing bariatric surgery (sleeve gastrectomy or
RYGB) for morbid obesity have been recruited into the Oxford GI
Biobank (Gastrointestinal Illness in Oxford: prospective cohort for out-
comes, treatment, predictors and biobanking with ethical approval from
Yorkshire & The Humber - Sheffield Research Ethics Committee, REC
Ref:11/YH/0020 and 16/YH/0247) REC Ref:11/YH/0020 and 16/YH/0247),
since November 2014. Written informed consent was obtained from
all study subjects. Blood samples were collected on the day of surgery,
and at 6 and 12months post-operatively, alongwith detailed clinical in-
formation. Pre-operation samples were taken under fasting conditions,
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starving post-surgical patients, and afternoon clinic visits. However,
the timing of blood sampling from the patients is expected to havemin-
imal or negligible effects on islet hormone secretion. Patient character-
istics are outlined in Table S1. Healthy control samples were obtained
from the Oxford Centre for Clinical Magnetic Resonance Research
(OCMR; Non-Invasive and Comprehensive Liver Assessment (NICOLA)
study; REC Ref13/SC/0243), details outlined in Table S1.2.2.2. Animals
Female C57BL6J mice (Charles River, US), aged 16–20 weeks, were
used for islet functional studies and female mice bred in house on a
C57BL/6 background, aged 16 to 24 weeks were used for colonic pri-
mary culture. Adult male 16–20 weeks-old Wistar rats as
normoglycaemic controls and age and sex matched diabetic GK rats
(Taconic, Denmark) were used as a model of type 2 diabetes. Data
from experiments done in mice and rats are not cross compared with
data generated from rats. All animal experiments were conducted in ac-
cordance with the UK Animals Scientific Procedures Act (1986) under
the UK Home Office Project License 70/7824 and were approved by
the University of Cambridge Animal Welfare and Ethical Review Body.2.3. Islet isolation
Mouse islets were isolated by liberase (Sigma-Aldrich Ltd., Gilling-
ham, UK) digestion as described previously [23].
Human pancreases were obtained with ethical approval and clinical
consent from non-diabetic donors. Islets were isolated in the Diabetes
Research &Wellness Foundation Human Islet Isolation Facility by colla-
genase digestion (Serva) usingmodified versions of published protocols
[24]. The donor isolated human islets that were used for secretion stud-
ies were obtained with research consent via the DRWFHuman Islet Iso-
lation Facility at which was established in 2006 in the Oxford Centre for
Diabetes, Endocrinology, and Metabolism in Oxford. The clinical islet
isolation facility is a purpose built, clean-room laboratory, licensed by
the Human Tissue Authority for the aseptic production of pancreatic
islet cells from cadaveric donor pancreases. It plays a pivotal role in
the supply of islets within the UK Islet Transplant Consortium (UKITC)
for the delivery of an NHS funded national therapy for the treatment
of type 1 diabetes in patients who have unstable diabetes with severe
complications. When islets cannot be transplanted and where there is
research consent, the isolated islets are made available for high quality
diabetes research projects. Human islets were used for experiments as
they became available. The robustness of each islet preparation is eval-
uated by the glucose-mediated insulin secretion index, which is calcu-
lated by dividing the mean insulin secretion at 20 mM glucose
(stimulatory concentration) by that at 1 mM glucose (basal concentra-
tion). Thus, a prep which is not glucose-responsive is regarded as poor
quality and one with at least a two-fold elevation in insulin secretion
in response to 20 mM glucose, is regarded as good quality islets.
Donor details are provided in Table S2.2.4. Roux-en-Y gastric bypass model
Sham or RYGB surgery was performed on anesthetized rats as previ-
ously described [8]. Briefly, the intestine was transected 10 cm distal to
the ligament of Treitz, creating a distal and a proximal end. The proximal
end was anastomosed to the intestine and a gastric pouch was created
(2–3% of total stomach). The distal end of the intestine was anasto-
mosed to the gastric pouch in an end-to-side fashion. For sham opera-
tion the animals were opened through a midline incision and the
viscera were gently manipulated.2.5. Measurements of serum concentrations of PYY, GLP-1 and IL-22
Subject details are reported in Table S1.1 and S1.2. Human serum
was kept at−80 °C until determination of hormones. Total PYY and glu-
cagon were measured by radioimmunoassay (Millipore and
Eurodiagnostica). Total GLP-1 and insulin were assayed using human
triplex kit (K15160C, Mesoscale Discovery). IL-22, IL-6 and IL-23 were
measured in plasma and serum samples by Human IL-22 or IL-6 or IL-
23 quantitative Elisa Kit (R&D systems).
For GK rats, blood was drawn from abdominal aorta at sacrifice
under ad-libitum feeding conditions and processed as described previ-
ously [25]. IL-22 was measured in serum samples by means of mouse/
rat IL-22 quantitative Elisa Kit (R&D systems).
2.6. Hormone secretion studies
Serum samples from the same patients before and 6 months after
bariatric surgery were used (Table S1.1). Islets were pre-cultured for
72 h in RPMI (5 mM glucose) with the addition of 20% pooled serum
in absence or presence of exendin (9–39; 1 μM; Bachem) or anti-PYY
antibody (1:500; ab22663, Abcam) as previously described [8]. For
each experiment, sera from two patients were pooled. Secretion exper-
iments were set with 12 hand-picked and size-matched islets per tube
(in triplicate). Islets were pre-incubated in Krebs-Ringer buffer (KRB)
containing 2mg/mL BSA and 3mmol/l glucose for 1 h at 37 °C, followed
by 1 h test incubation in KRB supplemented with glucose as indicated.
Insulin and glucagon content were determined by radioimmunoassay
(Millipore and Eurodiagnostica, respectively) according to themanufac-
turer's instructions. To allow comparison between experiments, secre-
tion data are presented as mean percent basal, where basal is
secretion at 1 mM glucose.
Secretion experiments under acute or chronic conditions were per-
formed as previously reported [13].
2.7. Measurements of PYY release from islets
20 islets per conditionwere cultured in 500 μLmedium in absence or
presence of propionate, butyrate and acetate (1mM; Sigma-Aldrich) or
GPBAR-A (30 μM; Sigma-Aldrich) or recombinant IL-22 (100 ng/mL;
R&D systems), each conditionwas set in triplicates. After the incubation
time, islets andmediumwere collected separately and stored at−20 °C
until determination of hormones. Total PYYwasmeasured in islet and in
the medium by radioimmunoassay (Millipore (human) and Phoenix
Pharmaceuticals (mouse) according to the manufacturer's instructions.
PYY release was normalized over the intra-islet PYY content to mini-
mize any variations due to differences in islet size. Analysis of intra-
islet PYY content onlywas performed in parallel to ensure no specific ef-
fect of the treatment on the total PYY levels in islets.
2.8. Gene expression analysis in colonic primary culture
Colonic primary cultures were prepared as previously described
[26,27] Colon and rectum were quickly isolated from mice sacrificed
by cervical dislocation, washed thoroughly with PBS and cleaned of
their outer muscle layer. Minced tissue was digested with 0.4 mg/mL
Collagenase XI (Sigma-Aldrich) at 37C to isolate crypts. Resuspended
crypts were plated on Matrigel coated wells in culture media (DMEM
high glucose supplemented with FBS10%, L-glutamine (2 mM), penicil-
lin (100U/mL), streptomycin (0.1mg/mL) and Y27632 (10 μM, Tocris)).
Plated crypts were washed the day after with fresh media and treated
for 72 h accordingly in duplicates, changing the media after the first
24 h. Media was removed and replaced by Trizol (Sigma) and RNA ex-
tracted using manufacturer's protocol and DNA removed incubating
RNA for 20 min at 37C with DNAse I (Invitrogen). 200 ng of RNA were
reverse transcripted (High capacity cDNA Reverse Transcription kit,
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versal Master mix (Life technologies) was performed on an
ABIquantStudio 7 (ThermoFisher Scientific) for Pyy, Gcg and β-actin
(Mm00520716, Mm00801714 and Mm02619580, Life technologies).
Data was analysed using the 2-ΔΔCt method with β-actin as reporter
gene and using the mean of the control duplicates as control. Statistical
difference was evaluated using a Dunn to control test from three differ-
ent experiments done in duplicates (R, PMCMR package).Fig. 1. Changes in PYY concentrations in human serum samples. Serum total PYY in
healthy volunteers (n = 20) and in patients before and 6 months after bariatric surgery
(n = 25). Data are presented as mean ± SEM. (One-way ANOVA for multiple
comparison) ⁎P b 0.05 for indicated comparison.2.9. PYY peptide quantification in colonic primary culture
The protein fraction from the Trizol extraction was extracted: after
theDNAprecipitation, protein are precipitatedwith 1.5 v/v cold acetone
for 10min, and the protein pellet after a 12,000 g 10 min centrifugation
at 4C is washed once with 1 mL of 0.3 M guanidine HCl in 95% ethanol,
once with 100% EtOH for 20min followed by a 5min 7500 g centrifuga-
tion at 4C. After the last wash, samples are air dried and resuspended in
8 M urea by incubation 30 min at 42C. Proteins are then precipitated
with 800uL ACN80% (in water) and peptides collected in the superna-
tant after 12,000 g 4C 10 min centrifugation and dried by vacuum cen-
trifugation. Peptides resupended in 0.1% formic acid are then purified
using a solid phase extraction (Oasis prime HLB, Waters) and eluted in
2 × 30 μL 60% MetOH, 30% H2O, 10% acetic acid and diluted with 75 μL
0.1% formic acid in solution.
Peptides were analysed on an H-Class Acquity (Waters) attached to
a TQ-XS triple quadrupole mass spectrometer (Waters). Sample (20 μL)
was injected onto a 2.1 × 50mm1.8 μmparticle HSS T3 Acquity column
held at 60 °C and flowing at 350 μL/min. Gradient starting conditionwas
99%A (0.1% formic acid inwater v/v) and1%B (0.1% formic acid in ACN).
Starting conditions were held for 0.25 min before raising to 50% B over
7 min. The column was flushed with 90% B for 1 min before returning
to starting conditions. The total time of each analysis was 10 min, with
the first 0.75 min and last 2 min diverted to waste. Mass spectrometry
conditions involved targeting four peptides using the transition and col-
lision energy details given below:PeptideP
P
P
P
O
OQ1
(m/z)Q3 (m/z) Collision energy
(eV)Dwell time
(ms)YY 1–36 1 664.4 732.4 20 25
YY 1–36 2 664.4 754.4 20 25
YY 3–36 1 707.7 847.5 20 25
YY 3–36 2 707.7 871.9 20 25
xyntomodulin
1742.6 680.7 22.5 25xyntomodulin
2742.6 923.7 22.5 25LP-II 1 943.0 1306.58 25 25GThe source parameters used included a positive electrospray ion
voltage of 3.0 kV, gas flow of 1000 L/h, desolvation temperature of 600
°C and a cone voltage of 40 V. Peptide peak areas were integrated
using the TargetLynx programassociatedwithMasslynxV 4.2 (Waters).2.10. Statistical analysis
Values are expressed as the mean ± standard error of the mean
(SEM). The statistical significance of differences was evaluated by the
Unpaired Student's t-test assuming unequal variation when two groups
were compared or by one way ANOVA and Bonferroni's multiple com-
parison tests when multiple groups were compared. A p value of
b0.05 was regarded as significant. Statistical analysis was performed
using GraphPad Prism.
Correlation analysis was performedwith Pearson's pairwise correla-
tion test (GraphPad).3. Results
3.1. Obese subjects have low circulating PYY levels, which are restored post-
bariatric surgery
Serum total PYY levels were measured in obese patients
before (mean ± SEM; BMI 47 ± 8.4) and six months after either
gastric bypass or sleeve gastrectomy (SG; mean ± SEM; BMI 37.5 ±
7.4; p b 0.0001) and compared with healthy volunteers (mean ±
SEM; BMI 22.24 ± 2.1) (Fig. 1). Serum PYY concentrations were 25%
lower in obese individuals compared to healthy people (mean ± SEM
in pg/mL; 125 ± 8.1 vs 164.5 ± 8.8, p-value = 0.002). Following both
RYGB and SG, serum PYY in obese patients increased to levels seen in
normal-weight individuals. Total GLP-1 levels were not significantly
changed by bariatric surgery (Fig. S1a). Circulating insulin levels,
which were markedly raised in obese individuals, decreased post-
operatively (Fig. S1b).
3.2. Improvement of human islet function post-surgery is mediated by PYY
Isolated human islets from three donors were cultured for 72 h in
the absence and presence of serum collected from patients before and
after bariatric surgery Following the culture period, insulin and gluca-
gon release were measuredat low (1 mM) and high (20 mM) glucose
concentrations. Islets exposed to pre-surgery serum exhibited a lack
of insulin release in response to 20mMglucose (Fig. 2a). In contrast, ap-
plication of the serum collected post-surgery resulted in a three-fold in-
crease in glucose-mediated insulin secretion, with no significant
alteration in the basal insulin level (Fig. 2a). Islets treated with the
post-surgery serum also exhibited normal suppression of glucagon at
20mM glucose (Fig. 2c). We hypothesized that humoral factors altered
by surgery, including circulating gut hormones, mediate the improve-
ments seen in insulin and glucagon secretion from islets. To further
test the possible involvement of systemic GLP-1, the GLP-1 receptor an-
tagonist exendin [9–39] was added to the serum during culture. Under
these conditions, GLP-1 receptor blockade did not affect glucose-
mediated insulin secretion. To explore if PYY is the humoral factor
mediating the beneficial effects of bariatric surgery on islet function in
man, islets from human donors were co-incubated with the post-
surgery serum and a PYY-specific antibody at a concentration
demonstrated to react with the peptide [13]. Immuno-neutralization
of PYY resulted in complete reversal of glucose-induced insulin release
(Fig. 2a). Chronic treatment of human islets with post-surgery
serum also resulted in increased insulin content (Fig. 2b), in agreement
with the effects of exogenously applied PYY on isolated islets [13].
On the other hand, both inhibition of GLP-1 signaling and
immunoneutralization of PYY showed a tendency to partially attenuate
Fig. 2. PYYmediatesmetabolic benefits of bariatric surgery. Insulin (a) and glucagon (c) secretion fromhuman islets (n=3donors n=3) treated for 72 hwith serum frompatients before
(pre) and 6months after surgery (post) in absence or presence of exendin [9–39] or PYY antibody. Secretion wasmeasured in islets stimulatedwith 1 mM (black bars) or 20mMglucose
(grey bars). Data are presented as percentage of basal secretion (mean± SEM as percentage of content). Insulin (b) and glucagon (d) content in human islets treated for 72 hwith serum
from patients before (pre) and 6 months after surgery (post). (One-way ANOVA for multiple comparison) ⁎P b 0.05, ⁎⁎P b 0.01for indicated comparison.
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was no change in islet glucagon content (Fig. 2d).
3.3. Which factors, altered by bariatric surgery, cause PYY elevation?
3.3.1. Propionate and bile acids mimic the effects of bariatric surgery by
inducing pancreatic PYY release and potentiating insulin secretion
Bacterial-derived metabolites, such as short chain fatty acids in-
crease in rodents and man following bariatric surgery [29,30] and can
directly modulate PYY secretion from L-cells [31,32]. To test if SCFAs
can also influence PYY release from islets ex vivo, mouse and human is-
lets were treated with propionate, butyrate and acetate. Of the three
SCFAs, only propionate resulted in a small but significant increase in
PYY secretion at 72 h in both human and mouse islets (Fig. 3a and b).
No difference in islet PYY content was observed between control and
propionate treatment at any time point (data not shown). Chronic
incubation of mouse islets with propionate also potentiated glucose-
stimulated insulin secretion (Fig. S2a), in agreementwith previous find-
ings [33].
Alteration in the enterohepatic circulation of bile acids is thought to
be another important mediator of the weight-independent benefits of
bariatric surgery [34]. Like SCFAs, bile acids can induce GLP-1 and PYY
release from enteroendocrine cells via activation of the bile acid recep-
tor TGR5 [35] which is also expressed on pancreatic islets [36]. Incuba-
tion of human islets with GPBAR-A, a potent agonist of TGR5, had no
effect on islet-derived PYY release (Fig. 3c) but resulted in enhancement
of glucose-stimulated insulin secretion (Fig. S2b), recapitulating previ-
ous findings in rodents [36]. In contrast to human islets, GPBAR-A
strongly elevated PYY secretion in mouse islets, and this effect was
sustained even after prolonged incubation (Fig. 3d).3.3.2. IL-22 is a new factor induced by bariatric surgery
A number of circulating inflammatory cytokines known to be ele-
vated in obesity are reduced following bariatric surgery, possibly as
a consequence of the substantial weight loss that occurs. IL-22 is an
inflammatory mediator of the innate and adaptive immune response
which also regulates adiposity and metabolic disorders [37]. Circulat-
ing IL-22 levels were assessed in healthy volunteers and obese pa-
tients before and six months after bariatric surgery. Compared to
levels before surgery, a significant increase in IL-22 concentrations
was observed in sera from post-surgery patients (Fig. 4a). A trend to-
wards increased IL-22 levels was also found in obese individuals in
comparison to healthy people. To test whether such elevation was
conserved in rodents after bariatric surgery we also explored IL-22
concentrations in serum samples from lean, diabetic GK rats after
RYGB or sham surgery. Compared to levels in the sham control sera,
a more pronounced elevation in IL-22 concentrations was noted in
sera from GK rats post-RYGB (Fig. S3a). In contrast to IL-22, circulating
levels of IL-6 and IL-23 were not altered by the surgery in humans
(Fig. 4b and c).3.3.3. IL-22 modulates PYY expression and release from enteroendocrine
cells and pancreatic islets
In our analysis the increase in circulating PYY after surgery correlates
with the increase in circulating IL-22 levels (Pearson r: 0.73) (Fig. S3b).
To test whether IL-22 directly induces PYY expression from
enteroendocrine cells, mouse colonic primary cultures were treated
with IL-22 for 6, 24, 48 and 72 h and PyymRNA levels were measured.
Stimulationwith IL-22 for 24 to 72 h significantly increased Pyy gene ex-
pression with the highest peak at 48 h incubation (Fig. 5a). Such
Fig. 3.Propionate and bile acids inducepancreatic PYY release. Human (donors n=9) (a, c) andmouse (micen=3) (b, d) isletswere incubatedwith 1mMpropionate, butyrate or acetate
or 30 μM GPBAR-A for the indicated time length (included in culture medium). Ratio between total PYY in the medium and in the islets is reported. ⁎⁎⁎P b 0.001, ⁎P b 0.05 for indicated
comparison.
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extracts by LC-MS (Fig. 5b).
In parallel, the effects of IL-22 on PYY release from pancreatic islets
were studied. Twenty-four hours exposure of isolated mouse and
human islets with the recombinant cytokine resulted in a small but sig-
nificant increase in PYY release (Fig. 5c and d).Of note, while theFig. 4. IL-22 levels increase after bariatric surgery. Plasma IL-22 (a), IL-6 (b) and IL-23 (c) in hea
25). Data are presented as mean ± SEM. (One-way ANOVA for multiple comparison) ⁎P b 0.05presence of IL-22 receptors on human pancreatic islets has been docu-
mented, we were unable to detect IL-22 in isolated islets [38].
IL-22 has been associated with preservation of insulin secretion in
isolated islets upon induction of cytokine-mediated oxidative and ER
stress. However, under physiological conditions, it does not affect
glucose-induced insulin release [22]. In line with this observation,lthy volunteers (n= 20) and in patients before and 6months after bariatric surgery (n =
for indicated comparison.
Fig. 5. IL-22 induces PYY gene expression and PYY secretion in pancreatic islets and primary colonic culture. (a, b) Expression of PYY gene (a) and protein (b) in colonic primary mouse
culture non-treated (NT) or exposed to 100ng/mL IL-22 for 6, 24, 48 and72h (micen=4). Data are presented as relative Pyy expression/protein to control (mean±SEM). Human (b) and
mouse (c) islets were treated with 100 ng/mL IL-22 for 24 h. Ratio between total PYY in the medium and in the islets is reported. ⁎P b 0.05 for indicated comparison.
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islets with IL-22 did not affect glucose-induced insulin release (Fig. S4),
suggesting that a direct compensatory effect of IL-22 occurs only on
compromised beta-cell function.
4. Discussion
A combination of factors, rather than a single one, is likely to account
for the compelling metabolic benefits associated with bariatric surgery.
PYY has been described as a classical weight loss-mediator and its role
in the metabolic benefits of surgery has largely been limited to its func-
tion as an appetite regulator. Here we show that, compared with levels
in healthy volunteers, total PYY levels are significantly lower in obese
people before surgery confirming its negative correlation with body
mass index (BMI) [39]. Sleeve gastrectomy and gastric bypass are the
twomost effective surgical procedures forweight loss and the induction
of remission in diabetes [40]. In association with a substantial reduction
in BMI in all patients six months post-surgery, a clear elevation in circu-
lating total PYY levels was noted after both types of operations. In con-
trast, there was no significant change in total GLP-1 levels in the same
serum samples at six months post-surgery. These findings are in agree-
ment with previous observations documented over the long-term fol-
lowing surgery [5,41,42]. Along with significant weight loss, a
reduction in HbA1c was observed in 71% of the patients in keeping
with improved glucose regulation. More recently, PYY has been de-
scribed as a critical factor in the restoration of impaired islet secretory
function after gastric bypass in the GK rat model of T2D [8] and exoge-
nous application of recombinant PYY has been demonstrated to poten-
tiate glucose-dependent insulin secretion in human islets from diabetic
donors [13]. However, an association between increased circulating PYY
concentrations and improved islet function post bariatric surgery in
humans has not been investigated previously. Using donor human islets
ex vivo and pre- and post-surgery sera, we show that improved glucose-
induced insulin and glucagon secretion that occurs post-surgery can beemulated in vitro. In particular, prolonged exposure of islets with sera
post-surgery restored the glucose-mediated inhibition of glucagon se-
cretion, which was lacking in islets exposed to pre-surgery sera,
whereby glucose tended to stimulate glucagon secretion, an observa-
tion consistent with those reported in islets from patients with T2D
[28]. These findings demonstrate that bariatric surgery can influence
islet function via blood-borne factors, which remain conserved in
serum.We also report that immuno-neutralization of PYY leads to com-
plete reversal of surgery-induced improved insulin secretion and a par-
tial, although not significant, reversal in glucagon release from human
islets treated with post-surgery serum. These data indicate that in
man, PYY acts as the humoral factor which mediates the beneficial ef-
fects of bariatric surgery on islets. It is noteworthy that chronic treat-
ment of islets with post-surgery serum induces the same fold increase
in insulin content as previously reported following chronic exposure
of islets to recombinant PYY [13], implying that elevation of insulin con-
tent in islets may be crucial for ameliorating beta-cell secretory
properties.
In addition to elevating circulating PYY levels in the GK rats, gastric
bypass surgery also leads to an increase in pancreatic PYY content (com-
pared to sham-operated controls) [13], thus providing a local (intra-
islet) source of PYY that may directly affect islet secretory functions.
However, the mechanism behind PYY elevation in islets post-surgery
remains unknown. Bariatric surgery significantly influences gut micro-
biota by altering the abundance of specific bacterial Phyla [43]. Short
chain fatty acids (SCFAs) are products of bacterial fermentationwith ac-
etate, propionate and butyrate being the most abundant. Increased
levels of SCFAs have been reported in rodents andman following bariat-
ric surgery, in particular after RYGB [29,30]. Like bacterial-derived me-
tabolites, bile acids are altered by bariatric surgery and are known to
modulate the release of gut hormones [35,44] and beta-cell function
[33,36]. However, their impact on islet-derived PYY has not been stud-
ied previously. Our results demonstrate that prolonged treatment
with the short chain fatty acid propionate can lead to a modest increase
74 C. Guida et al. / EBioMedicine 40 (2019) 67–76in PYY release frommouse and human isolated islets. Although this de-
layed response cannot be fully explained, we speculate that it might be
secondary to alteration in gene expression and expression of intermedi-
ate factors. In addition, the activation of the bile acid receptor TGR5
which is expressed on pancreatic beta-cells [36], results in a prominent
induction of islet-derived PYY in mice. This effect was not observed in
human islets, suggesting a possible species-specific impact of bile acid
changes on gut-dependent PYY production. Bile acids are increasingly
recognized as important regulators of lipid and glucose metabolism
[45]. In patients, fasting and postprandial bile acid concentrations rise
following RYGB, while conflicting results have been reported after SG
[34,46]. Restoration of glucose-dependent insulin secretion post-
surgery could be attributed to increased levels of bile acids since activa-
tion of the bile acid sensors FXR [47] and TGR5 [36] has been shown to
enhance insulin release in isolated islets. Consistent with these reports,
we observe that 1 h stimulation of TGR5 by the agonist GPBAR-A poten-
tiates glucose-stimulated insulin secretion in human islets, even when
the donor human islets were poorly responsive to glucose, probably
due to their sub-optimal quality (purity b50%; viabilityb50%). Collec-
tively these data indicate that propionate and bile acids can enhance
glucose-induced insulin secretion both directly and indirectly via in-
creased release of PYY from the gut and islets (Fig. 6).
Obesity and the metabolic syndrome are accompanied by a ‘low
grade’ chronic inflammation, indicated by a well-characterized positive
association between obesity indices and inflammatory markers, such as
C reactive protein (CRP) and IL-6 [48]. Thus, weight loss triggered by
bariatric surgeries is expected to lead to a reduction in the circulating
levels of inflammatory mediators, often seen more than six months
after the operation [18,19]. To date, there is a lack of consensus regard-
ing the changes in IL-6 levels following weight-loss surgery. Whereas,
some studies have documented a substantial post-operative decrease
[49–51], Miller et al. has reported no significant changes in IL-6 six
months after gastric bypass [20]. These latter reports are consistent
with our findings in which IL-6 and IL-23 levels were unaffected by bar-
iatric surgery in humans. On the other hand, post-surgery elevation in
IL-22 that we observe here is a novel finding deserving further study.
In the last years the roles of this cytokine have been extended beyond
host defense and inflammation in the intestine and include protective
effects in different metabolic conditions. For example, IL-22 influences
lipid metabolism in the liver, reduces lipogenesis and amelioratesFig. 6. Increased PYY levels in circulation and in islets occur via several factors and jointly
contribute to restoration of islet function after bariatric surgery. GSIS = glucose-
stimulated insulin secretion.hepatic steatosis induced by high fat diet [52]. Thus, it is plausible to
speculate that its elevation after bariatric surgery might contribute to
the improvement in steatosis and nonalcoholic fatty liver disease re-
ported in patients [53].
Unlike other cytokines, IL-22 also protects pancreatic islets from
oxidative andER stress andpreserves their secretory functions,whilst op-
posite effects are mediated by IL-23, a cytokine upstream of IL-22 [22].
Due to its unique role in alleviatingmetabolic disorders and its direct re-
storative effect on pancreatic beta-cells, IL-22 constitutes an important
factor potentially mediating post-surgery anti-diabetic and beneficial
metabolic effects. It is noteworthy that the GK rat represents a lean dia-
betic model. Nevertheless, IL-22 is highly elevated post-surgery in these
rats, indicating that its physiological roles are independent of weight.
In line with previous reports, acute or chronic treatment islets iso-
lated from healthy human donors with IL-22 failed to enhance insulin
secretion, suggesting that IL-22 is not a potentiator of insulin secretion
per se, but that it might act to preserve or restore islet function under
stressful conditions. Yet it remains unknown if IL-22 has a direct effect
on compromised islets from diabetic donors. Among its multiple posi-
tive influences on metabolic disease, IL-22 injection in obese mice
leads to increased serum PYY levels which is thought to contribute to
the reduction in food intake and weight [21]. This increase in PYY is
likely to be caused by IL-22-mediated stimulation of PYY expression in
enteroendocrine L-cells, as indicated by our data. We only detected a
mild increase in islet-derived PYY, which on its own, may be too small
to directly impact on islet hormone secretion. Thus, it is likely that
under physiological conditions, IL-22 indirectly modulates insulin se-
cretion mainly via elevation in PYY release from L-cells (Fig. 6). Taken
together our data demonstrate that PYY is a critical humoral factor
which mediates enhanced islet secretory function, thus contributing to
diabetes remission in humans upon bariatric surgery. Whereas there is
no way to differentiate between the contribution of circulating and
islet-derived PYY, it is likely they both contribute to restore islet func-
tion and sustain this effect over long-term. We postulate that modula-
tion of blood-borne factors such as propionate, bile acids and IL-22 can
increase overall PYY levels, which may subsequently influence islet
function, resulting in improved insulin and glucagon secretion. Due to
shortage of human serum samples we did not analyse changes in PYY
[3–36], which constitutes another major endogenous form of PYY likely
to affect insulin release. Nevertheless, thesefindings providenewmech-
anistic links with key factors induced by bariatric surgery, restoration of
impaired islet function and diabetes correction.
Bariatric surgery as a treatment option for type 2 diabetes (rather
than for weight-loss alone) has been endorsed by 50 international
health organizations. However, surgery remains invasive, irreversible
and not suitable for all patients with T2D, highlighting the urgent
need for medical therapies as alternatives. Using a unique translational
researchparadigmcombining serum frompatients before and following
surgery with isolated human islets, our study demonstrates that the
metabolic benefits of bariatric surgery can be emulated ex vivo, giving
rise to the possibility of identifying the criticalmediators of these effects.
While our analysis focuses on the regulation of PYY and its effects on
islet secretory functions, it is likely that other factors also contribute to
achieve the metabolic benefits elicited by surgery, including improve-
ments in peripheral tissue insulin sensitivity or tissue glucose clearance,
and a combination of therapies may be required to successfully over-
come the need for this invasive and irreversible procedure. Particularly,
we foresee that the addition of PYY analogues to other incretinmimetics
would potentiate and sustain their long-term efficacy. Moreover, the
identification of factors specifically triggering PYY induction both sys-
temically and within the islets, may pave the way for an alternative
cure to peptide therapeutics, thus overcoming their inherent weak-
nesses, like poor pharmacokinetic properties and stabilities, and yet
achieving the same benefits for the treatment of diabetes.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.12.040.
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